Avenue Therapeutics Inc. Stock
Avenue Therapeutics Inc. Stock
Avenue Therapeutics Inc. dominated the market today, gaining €0.019 (22.820%).
With 0 Sell predictions and 2 Buy predictions the community sentiment towards the Avenue Therapeutics Inc. stock is not clear.
Our community identified positive and negative aspects for Avenue Therapeutics Inc. stock for the coming years. 3 users see the criterium "Company culture" as a plus for the Avenue Therapeutics Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Avenue Therapeutics Inc. in the next few years
Pros
?
B****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Avenue Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Avenue Therapeutics Inc. | 22.820% | - | - | - | - | - | - |
| Gritstone Oncology Inc | 13.680% | 16.156% | -19.102% | -60.022% | -52.018% | -88.090% | - |
| Avid Bioservices Inc | 0.700% | 5.109% | 24.138% | -55.556% | 18.033% | -60.000% | 78.174% |
| Pacira Pharmaceuticals | 3.310% | 4.167% | -3.101% | -39.614% | -16.107% | -50.000% | -41.038% |
Comments
Avenue Therapeutics, Inc. (NASDAQ: ATXI) is now covered by analysts at Maxim Group. They set a "buy" rating and a $0.75 price target on the stock.
Show more
Ratings data for ATXI provided by MarketBeat
Avenue Therapeutics, Inc. (NASDAQ: ATXI) is now covered by analysts at Aegis. They set a "buy" rating and a $32.00 price target on the stock.
Show more
Ratings data for ATXI provided by MarketBeat
